According to lots of medical surveys done by the concerned doctors and various reputed pharmaceutical companies that a large number of breast cancer patients in the U.S. receive Sanofi’s chemotherapy drug, Taxotere, as a part of their treatment.
Though, few women who were left with mutilating, permanent hair loss from the drug are filing lawsuits against Sanofi. They claim that the manufacturer of this drug failed to warn them and even hided the risk from them as well as from their health care providers.
Note: Even the lawsuit concerning the chemotherapy drug Taxotere states that the manufacturer of Taxotere (Sanofi-Aventis) failed to warn patients and physicians of the augmented risks of perpetual alopecia (loss of hair).
In recent years, continuously claims are being filed against Sanofi-Aventis by women who have suffered permanent hair loss as a result of being prescribed Taxotere. “Taxotere Permanent Hair Loss Lawsuit Attorney” states that if in the past manufacturer had specifically warned of the risks allied to the drug, patients would have been prescribed a different chemotherapy drug called Taxol, which is far more effective than Taxotere, and does not result in permanent hair loss.
Now pay attention here…….
What are the Allegations in the Taxotere Litigation?
1) Taxotere is defective and unreasonably dangerous;
2) Sanofi-Aventis was negligent in the manufacturing of Taxotere;
3) Sanofi-Aventis failed to properly test Taxotere, and failed to warn doctors and patients of the potential for alopecia; and
4) Sanofi-Aventis concealed evidence of the dangers of Taxotere, and misrepresented the effectiveness and safety of it in its marketing materia.
Taxotere (docetaxel) is just a chemotherapy drug approved in treating breast cancer, non-small cell lung cancer, advanced stomach cancer, head and neck cancer and metastatic prostate cancer. It is administered intravenously via a vein, and is member of a family of drugs called taxanes. It is used to attempt to prevent cancer cells from growing and dividing.